TSE:4502Pharmaceuticals
Takeda’s Narcolepsy Review And AI Deal Tested Against Rich Valuation
Takeda Pharmaceutical received FDA priority review for its orexin agonist for narcolepsy type 1, marking an important regulatory milestone for the therapy.
The company also announced a multi year AI drug discovery collaboration with Iambic, focused on oncology and gastrointestinal candidates.
Both developments arrive as Takeda Pharmaceutical (TSE:4502) trades at ¥5,614.0 per share.
Takeda Pharmaceutical (TSE:4502) enters these announcements with a share price of ¥5,614.0 and multi year...